Gritstone bio, Inc. Overview
Pro stress-test →Gritstone bio discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company uses self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd) vectors to elicit desired immune responses. The company faces severe financial distress following bankruptcy restructuring.
Strategic Profile
Pro stress-test →The company's two oncology programs in clinical-stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has also developed a COVID-19 vaccine candidate supported by U.S. government contracts and is researching a functional cure for HIV in collaboration with the National Institutes of Health.
Competitive Landscape
Pro stress-test →Gritstone competes in the personalized cancer immunotherapy and vaccine development space against larger, better-capitalized biotechs including Moderna, BioNTech, and Inovio. However, bankruptcy and delisting have effectively removed it from active competition. The company's neoantigen-personalized approach competes conceptually with similar therapies from larger oncology platforms.
Industry Context
Gritstone bio, Inc. operates in Biotechnology - Immunotherapy & Oncology.
Key facts
Founded: 2015 · Headquarters: Emeryville, US · Market cap: $3.8M